Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370668 | 1.00 | HSD17B10 (0.42) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL1031139 | 1.00 | HSD17B10 (0.42) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL1031142 | 1.00 | HSD17B10 (0.42) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL2370251 | 1.00 | HSD17B10 (0.42) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL2370658 | 1.00 | HSD17B10 (0.42) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL5849203 | 0.86 | GPR119 (0.47) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL7487281 | 0.86 | GPR119 (0.47) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL5849057 | 0.86 | GPR119 (0.47) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL5849198 | 0.86 | GPR119 (0.47) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 | |
| SCHEMBL6012032 | 0.82 | MEN1 (0.53) | HSD17B10ALDH1A1LMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237550-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | TARGACEPT, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2544690-A2 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | Targacept Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112428-A2 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | TARGACEPT, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237550-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | SLC10A2, MLNR, VIP | HSD17B10 2348/4885ALDH1A1 1001/4885LMNA 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.